Esmo Congress 2012: Molmed Presented Three Studies On Its Ngr-htnf Posted By: Molmed

MolMed S.p.A. (MLM.MI) presented, at the 37th ESMO Congress, three studies on its investigational biological drug NGR-hTNF, including updated results in non-small cell lung cancer (NSCLC) patients and two retrospective analyses evaluating potential predictors of outcome in patients enrolled in Phase I and Phase II trials.
Long-term efficacy analysis confirms the potential clinical benefit in lung cancer patients with squamous cell histology
Pooled efficacy analyses reveal that early drug effects strongly correlate with improved patient outcome

1 October 2012 ""Long-term results (median follow-up of 20 months) presented by MolMed at the meeting validate previously presented data and confirm the potential clinical benefit of NGR-hTNF treat ...Molmed, NGR-hTNF, ESMO Congress 2012

balance transfer calculator top cash back credit cards top interest rates